Veracyte Inc’s recent filing unveils that its Director EASTHAM KARIN unloaded Company’s shares for reported $0.12 million on Jun 13 ’25. In the deal valued at $26.66 per share,4,590 shares were sold. As a result of this transaction, EASTHAM KARIN now holds 13,907 shares worth roughly $0.32 million.
Then, Bhanji Muna sold 4,589 shares, generating $122,367 in total proceeds. Upon selling the shares at $26.67, the Director now owns 29,989 shares.
Before that, KARIN EASTHAM bought 4,590 shares. Veracyte Inc shares valued at $122,507 were divested by the Director at a price of $26.69 per share.
Craig Hallum initiated its Veracyte Inc [VCYT] rating to a Buy in a research note published on March 20, 2025; the price target was $45. A number of analysts have revised their coverage, including Goldman’s analysts, who decreased its forecast for the stock in early December from “a Buy” to “a Neutral”. Wolfe Research began covering VCYT with “an Outperform” recommendation on November 15, 2024. UBS started covering the stock on October 16, 2024. It rated VCYT as “a Buy”.
Price Performance Review of VCYT
On Monday, Veracyte Inc [NASDAQ:VCYT] saw its stock fall -2.04% to $23.03. Over the last five days, the stock has lost -13.58%. Veracyte Inc shares have fallen nearly -8.90% since the year began. Nevertheless, the stocks have fallen -41.84% over the past one year.
How much short interest is there in Veracyte Inc?
A steep rise in short interest was recorded in Veracyte Inc stocks on 2025-06-13, growing by 0.73 million shares to a total of 5.94 million shares. Yahoo Finance data shows the prior-month short interest on 2025-05-15 was 5.21 million shares. There was a rise of 12.27%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on October 10, 2024 when Guggenheim began covering the stock and recommended ‘”a Buy”‘ rating along with a $40 price target.
